ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > ProMIS Neurosciences faces Nasdaq delisting risk

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Aug 07, 2024 2:32pm

106 Views

Post# 36167960

RE:ProMIS Neurosciences faces Nasdaq delisting risk

This is from July 5. Pretty sure I saw somewhere a week or two ago that they were off the hook when the priced jumped up to over $2.

But the way things are going now, they might find themselves facing the same risk again.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments